Molecule intelOpportunity: StrongEssential

Cytarabine

18 brands · 9 companies · product forms

ATC: L01BC01

Opportunity snapshot

Launch attractiveness
50
Market saturation
25
Price room
100
Regulatory risk
0
18
brands
9
companies
Rs 970.75
median price
20
price points
9.93x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 17%

Price room

Across observed sources and strengths
CheapestRs 207.96
MedianRs 970.75
Most expensiveRs 2,065.3
Spread9.93×
Sources: DRAP-official, Servaid

max/min price ratio 9.93x across 20 trusted points (Rs 207.96-2065.3). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Cytarabine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(75) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

9 canonical companies and 18 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 9.93x across 20 trusted points (Rs 207.96-2065.3). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.